Drug delivery techniques for treating age-related macular degeneration

Stephen Schwartz, Ingrid U. Scott, Harry W Flynn, Michael W. Stewart

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Introduction: Currently, the standard therapy for neovascular age-related macular degeneration involves the use of anti-vascular endothelial growth factor (VEGF) drugs, which are delivered by repeated office-based intravitreal injections. This treatment is generally very effective in stabilizing or improving vision, although repeated injections create a burden for patients, family members and physicians. In addition, the cumulative risks of endophthalmitis and other complications increase with the number of injections. Areas covered: In the clinic, much attention is focused on the relative efficacies of the three major anti-VEGF medications (bevacizumab, ranibizumab and aflibercept) as well as the most popular re-injection regimens (monthly, as-needed and treat-and-extend). In theory, intravitreal anti-VEGF drug delivery with sustained-release devices would offer similar visual results with fewer required re-injections. Various approaches have been studied, including noninvasive techniques, intraocular implants and colloidal carriers, such as liposomes, microparticles and nanoparticles. Expert opinion: Despite its theoretical appeal, sustained-release drug delivery will not replace current techniques unless it offers one or more advantages in efficacy, safety, convenience or cost. Currently, many patients maintain stable vision with intravitreal injections at intervals of 2 months or longer, so sustained-release techniques will have to lengthen these intervals substantially to become widely accepted. As we continue to collect data from clinical trials, the role of sustained-release techniques will become better defined.

Original languageEnglish
Pages (from-to)61-68
Number of pages8
JournalExpert Opinion on Drug Delivery
Volume11
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Macular Degeneration
Vascular Endothelial Growth Factor A
Intravitreal Injections
Injections
Pharmaceutical Preparations
Endophthalmitis
Family Physicians
Expert Testimony
Liposomes
Nanoparticles
Clinical Trials
Safety
Costs and Cost Analysis
Equipment and Supplies
Therapeutics

Keywords

  • Age-related macular degeneration
  • Choroidal neovascularization
  • Intravitreal injection
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Drug delivery techniques for treating age-related macular degeneration. / Schwartz, Stephen; Scott, Ingrid U.; Flynn, Harry W; Stewart, Michael W.

In: Expert Opinion on Drug Delivery, Vol. 11, No. 1, 01.01.2014, p. 61-68.

Research output: Contribution to journalArticle

@article{d13f5ab30ae7411bb353aedbafadf7d5,
title = "Drug delivery techniques for treating age-related macular degeneration",
abstract = "Introduction: Currently, the standard therapy for neovascular age-related macular degeneration involves the use of anti-vascular endothelial growth factor (VEGF) drugs, which are delivered by repeated office-based intravitreal injections. This treatment is generally very effective in stabilizing or improving vision, although repeated injections create a burden for patients, family members and physicians. In addition, the cumulative risks of endophthalmitis and other complications increase with the number of injections. Areas covered: In the clinic, much attention is focused on the relative efficacies of the three major anti-VEGF medications (bevacizumab, ranibizumab and aflibercept) as well as the most popular re-injection regimens (monthly, as-needed and treat-and-extend). In theory, intravitreal anti-VEGF drug delivery with sustained-release devices would offer similar visual results with fewer required re-injections. Various approaches have been studied, including noninvasive techniques, intraocular implants and colloidal carriers, such as liposomes, microparticles and nanoparticles. Expert opinion: Despite its theoretical appeal, sustained-release drug delivery will not replace current techniques unless it offers one or more advantages in efficacy, safety, convenience or cost. Currently, many patients maintain stable vision with intravitreal injections at intervals of 2 months or longer, so sustained-release techniques will have to lengthen these intervals substantially to become widely accepted. As we continue to collect data from clinical trials, the role of sustained-release techniques will become better defined.",
keywords = "Age-related macular degeneration, Choroidal neovascularization, Intravitreal injection, Vascular endothelial growth factor",
author = "Stephen Schwartz and Scott, {Ingrid U.} and Flynn, {Harry W} and Stewart, {Michael W.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1517/17425247.2013.859135",
language = "English",
volume = "11",
pages = "61--68",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Drug delivery techniques for treating age-related macular degeneration

AU - Schwartz, Stephen

AU - Scott, Ingrid U.

AU - Flynn, Harry W

AU - Stewart, Michael W.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Introduction: Currently, the standard therapy for neovascular age-related macular degeneration involves the use of anti-vascular endothelial growth factor (VEGF) drugs, which are delivered by repeated office-based intravitreal injections. This treatment is generally very effective in stabilizing or improving vision, although repeated injections create a burden for patients, family members and physicians. In addition, the cumulative risks of endophthalmitis and other complications increase with the number of injections. Areas covered: In the clinic, much attention is focused on the relative efficacies of the three major anti-VEGF medications (bevacizumab, ranibizumab and aflibercept) as well as the most popular re-injection regimens (monthly, as-needed and treat-and-extend). In theory, intravitreal anti-VEGF drug delivery with sustained-release devices would offer similar visual results with fewer required re-injections. Various approaches have been studied, including noninvasive techniques, intraocular implants and colloidal carriers, such as liposomes, microparticles and nanoparticles. Expert opinion: Despite its theoretical appeal, sustained-release drug delivery will not replace current techniques unless it offers one or more advantages in efficacy, safety, convenience or cost. Currently, many patients maintain stable vision with intravitreal injections at intervals of 2 months or longer, so sustained-release techniques will have to lengthen these intervals substantially to become widely accepted. As we continue to collect data from clinical trials, the role of sustained-release techniques will become better defined.

AB - Introduction: Currently, the standard therapy for neovascular age-related macular degeneration involves the use of anti-vascular endothelial growth factor (VEGF) drugs, which are delivered by repeated office-based intravitreal injections. This treatment is generally very effective in stabilizing or improving vision, although repeated injections create a burden for patients, family members and physicians. In addition, the cumulative risks of endophthalmitis and other complications increase with the number of injections. Areas covered: In the clinic, much attention is focused on the relative efficacies of the three major anti-VEGF medications (bevacizumab, ranibizumab and aflibercept) as well as the most popular re-injection regimens (monthly, as-needed and treat-and-extend). In theory, intravitreal anti-VEGF drug delivery with sustained-release devices would offer similar visual results with fewer required re-injections. Various approaches have been studied, including noninvasive techniques, intraocular implants and colloidal carriers, such as liposomes, microparticles and nanoparticles. Expert opinion: Despite its theoretical appeal, sustained-release drug delivery will not replace current techniques unless it offers one or more advantages in efficacy, safety, convenience or cost. Currently, many patients maintain stable vision with intravitreal injections at intervals of 2 months or longer, so sustained-release techniques will have to lengthen these intervals substantially to become widely accepted. As we continue to collect data from clinical trials, the role of sustained-release techniques will become better defined.

KW - Age-related macular degeneration

KW - Choroidal neovascularization

KW - Intravitreal injection

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84890643919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890643919&partnerID=8YFLogxK

U2 - 10.1517/17425247.2013.859135

DO - 10.1517/17425247.2013.859135

M3 - Article

C2 - 24219407

AN - SCOPUS:84890643919

VL - 11

SP - 61

EP - 68

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 1

ER -